BD - Earth day 2024

New Wearable Holter Device Launched by UltraLinQ, Featuring UbiqVue ECG Analysis and Interpretation Software

Friday, February 23, 2024

In honor of American Heart Month, UltraLinQ is thrilled to unveil its latest innovation: the Holter Program featuring the UbiqVue Holter and ECG Interpretation Software. This cutting-edge biosensor, combined with advanced ECG analysis and interpretation software, simplifies the process of uploading, analyzing, and managing ECG data and reports. Specifically designed to meet the complex requirements of modern cardiology practices, this platform ensures seamless, accessible, and scalable cardiac care.

The Holter device is remarkably lightweight at just 28 grams and is disposable, offering two channels for continuous monitoring for up to 5 days. Equipped with an event indicator for patient-reported events, it can be worn during various activities such as sleep, exercise, and showering, without disrupting daily routines. Its wireless and motion-tolerant design guarantees accurate diagnostics while allowing patients to go about their day uninterrupted. Coupled with UbiqVue, users have access to a comprehensive suite of viewing and analysis tools, simplifying the entire workflow from data collection to report finalization.

UbiqVue streamlines the clinical workflow, enabling immediate data upload, retrieval, and interpretation. Continuous monitoring is crucial for capturing sporadic events and arrhythmias that may be overlooked during routine visits. By providing superior data quality, advanced interpretation tools, and streamlined reporting workflows, UltraLinQ's Holter program enhances accessibility and manageability of high-quality cardiac care.

Clinical studies have shown that UltraLinQ's Holter Program detects arrhythmias in more patients compared to traditional monitors*, especially improving the identification of atrioventricular (AV) block and premature ventricular contractions (PVCs) due to its enhanced P-wave quality.